Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a synthetic biology platform company that completed its de-SPAC merger with Soaring Eagle Acquisition Corp., sponsored by Eagle Equity Partners, in September 2021, bringing the combined entity to the public markets within the biotechnology and life sciences sector. The company filed an S-1/A amendment with the SEC on September 27, 2022, under accession number 0001193125-22-252446, as part of its ongoing post-merger registration obligations. Ginkgo operates as a publicly traded entity designing custom organisms for partners across pharmaceuticals, agriculture, and industrial applications. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time SPAC transaction data on Ginkgo Bioworks and hundreds of other de-SPAC names.